No case of COX‐1‐related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography

References

• Patrono C., Garcia Rodriguez L. A., Landolfi R., Baigent C. Low‐dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373–83
   PubMed Web of Science ®Google Scholar
• Rao G. H., Michiels J. J. Aspirin resistance: does it exist?. Semin Thromb Hemost 2007; 33: 210–14
   PubMed Web of Science ®Google Scholar
• Gurbel P. A., Tantry U. S. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 2006; 19: 439–48
   PubMedGoogle Scholar
• Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073–6
   PubMed Web of Science ®Google Scholar
• Burch J. W., Stanford N., Majerus P. W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314–19
   PubMed Web of Science ®Google Scholar
• Awtry E. H., Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18
   PubMed Web of Science ®Google Scholar
• Weksler B. B., Kent J. L., Rudolph D., Scherer P. B., Levy D. E. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985; 16: 5–9
   PubMed Web of Science ®Google Scholar
• Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994–8
   PubMed Web of Science ®Google Scholar
• Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low‐dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980–7
   PubMed Web of Science ®Google Scholar
• Maree A. O., Fitzgerald D. J. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175–81
   PubMed Web of Science ®Google Scholar
• Maree A. O., Curtin R. J., Dooley M., et al. Platelet response to low‐dose enteric‐coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258–63
   PubMed Web of Science ®Google Scholar
• Tantry U. S., Bliden K. P., Gurbel P. A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705–9
   PubMed Web of Science ®Google Scholar
• Helgason C. M., Tortorice K. L., Winkler S. R., et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345–50
   PubMed Web of Science ®Google Scholar
• Wang T. H., Bhatt D. L., Topol E. J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647–54
   PubMed Web of Science ®Google Scholar
• Gum P. A., Kottke‐Marchant K., Welsh P. A., White J., Topol E. J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–5
   PubMed Web of Science ®Google Scholar
• Schwartz K. A., Schwartz D. E., Ghosheh K., Reeves M. J., Barber K., DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973–5
   PubMed Web of Science ®Google Scholar
• Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004; 147: 293–300
   PubMed Web of Science ®Google Scholar
• Catella F., Healy D., Lawson J. A., FitzGerald G. A. 11‐Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861–5
   PubMed Web of Science ®Google Scholar
• Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S. Aspirin‐resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–5
   PubMed Web of Science ®Google Scholar
• Bruno A., McConnell J. P., Cohen S. N., et al. Serial urinary 11‐dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 2004; 35: 727–30
   PubMed Web of Science ®Google Scholar
• Perneby C., Wallen N. H., Rooney C., Fitzgerald D., Hjemdahl P. Dose‐ and time‐dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652–8
   PubMed Web of Science ®Google Scholar
• Violi F., Pignatelli P. Aspirin resistance: is this term meaningful?. Curr Opin Hematol 2006; 13: 331–6
   PubMed Web of Science ®Google Scholar
• Blacklock C. J., Lawrence J. R., Wiles D., et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non‐vegetarians, and patients taking low dose aspirin. J Clin Pathol 2001; 54: 553–5
   PubMed Web of Science ®Google Scholar
• Lev E. I., Patel R. T., Maresh K. J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27–33
   PubMed Web of Science ®Google Scholar
• Zimmermann N., Kienzle P., Weber A. A., et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982–4
   PubMed Web of Science ®Google Scholar
• Payne D. A., Jones C. I., Hayes P. D., Webster S. E., Ross N. A., Goodall A. H. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?. Thromb Haemost 2004; 92: 89–96
   PubMed Web of Science ®Google Scholar
• Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542–7
   PubMed Web of Science ®Google Scholar
• Golanski J., Chlopicki S., Golanski R., Gresner P., Iwaszkiewicz A., Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit 2005; 27: 484–90
   PubMed Web of Science ®Google Scholar
• Cornelissen J., Kirtland S., Lim E., et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 2006; 95: 476–82
   PubMed Web of Science ®Google Scholar
• Cipollone F., Ciabattoni G., Patrignani P., et al. Oxidant stress and aspirin‐insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007–13
   PubMed Web of Science ®Google Scholar